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Abstract
Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally. The objective of this study was to
determine the distribution and clonal type variability of three potential vaccine antigens: Pneumococcal serine-rich repeat
protein (PsrP), Pilus-1, and Pneumococcal choline binding protein A (PcpA) among pneumococcal isolates from children
with invasive pneumococcal disease and healthy nasopharyngeal carriers. We studied by Real-Time PCR a total of 458
invasive pneumococcal isolates and 89 nasopharyngeal pneumococcal isolates among children (total = 547 strains)
collected in Barcelona, Spain, from January 2004 to July 2010. pcpA, psrP and pilus-1 were detected in 92.8%, 51.7% and
14.4% of invasive isolates and in 92.1%, 48.3% and 18% of carrier isolates, respectively. Within individual serotypes the
prevalence of psrP and pilus-1 was highly dependent on the clonal type. pcpA was highly prevalent in all strains with the
exception of those belonging to serotype 3 (33.3% in serotype 3 isolates vs. 95.1% in other serotypes; P,.001). psrP was
significantly more frequent in those serotypes that are less apt to be detected in carriage than in disease; 58.7% vs. 39.1%
P,.001. Antibiotic resistance was associated with the presence of pilus-1 and showed a negative correlation with psrP.
These results indicate that PcpA, and subsequently Psrp and Pilus-1 together might be good candidates to be used in a
next-generation of multivalent pneumococcal protein vaccine.
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Introduction
Invasive disease caused by Streptococcus pneumoniae is responsible
for more than 1.6 million childhood deaths worldwide every year
[1]. In certain developed countries, including Spain, despite
vaccination with a 7-valent conjugate vaccine against capsular
polysaccharide (PCV-7), pneumococcal pneumonia remains a ma-
jor cause of pediatric hospital admission [2,3,4]. PCV-7 is
composed of capsular polysaccharide from serotypes 4, 6B, 9V,
14, 18C, 19F, and 23F individually conjugated to diphtheria
CRM197 and has proved to be effective in preventing pneumo-
coccal disease caused by these serotypes in children [5]. PCV7 also
prevents invasive pneumococcal disease (IPD) in adult and non-
vaccinated children by an indirect effect (herd immunity) on
pneumococcal transmission [5,6]. Importantly, nowadays evi-
dence exists of the emergence of non-vaccine serotypes in children
and adults to occupy this vaccine-emptied niche, thereby partially
eroding the benefit of PCV-7 [3,7,8,9]. For example, in Spain
disease caused by serotype 19A was responsible for 13.5% of
pediatric IPD during the period 2000–2008, whereas in 2000, at
the time of introduction of PCV-7, serotype 19A only accounted
for 4.6% of pediatric infections [10]. The pneumococcus is also
a primary cause of otitis media and PCV-7 only slightly reduces
the rate of disease [11]. At present, more than 1,500,000 cases
occur annually in the United States, with an estimated cost of
440 million U.S. dollars [12]. Thus, pneumococcal disease
remains a major medical problem with an urgent need for an
improved vaccine.
Due to these limitations, other conjugate vaccines with a larger
number of serotypes have been recently commercialized. These
include a 10-valent conjugate vaccine (PCV10), which includes the
seven serotypes of PCV7 plus serotypes 1, 5 and 7F and PCV13
(PCV10 plus additional serotypes 3, 6A and 19A). These vaccines
will most likely continue to reduce the burden of invasive
pneumococcal disease and are becoming increasingly available
in underdeveloped countries due to efforts of institutions such as
The Bill and Melinda Gates Foundation through GAVI Alliance
[13,14]. However, due to the high cost of the conjugation process,
these vaccines are limited in the number of serotypes that can be
included in an affordable vaccine. The current cost for each dose
of PCV13 is $100–125, with three immunizations recommended.
An alternate vaccine strategy is the use of a serotype-
independent vaccine using conserved common pneumococcal
protein antigens. These might stand alone, or replace the
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diphtheria toxoid in the conjugate vaccine and thereby enhance
coverage of the existing vaccines. To date, numerous preclinical
studies have shown that different pneumococcal proteins confer
protection against pneumococcal challenge and that a combina-
tion of multiple proteins confers superior protection. The main
advantage of a protein vaccine is that protection would not be
serotype dependent and fewer antigen candidates could offer a
high coverage with a lower cost of manufacturing. For these
reasons, studies are warranted in determining if a next-generation
of a multivalent protein vaccine against pneumococcus is feasible
and desirable.
The objective of the present study was to determine the
distribution and clonal type variability of three novel potential
vaccine candidates: Pneumococcal serine-rich protein (PsrP), Pilus-
1, and Pneumococcal choline binding protein A (PcpA). PsrP is a
serine rich repeat protein (SRRP) previously demonstrated to be
responsible for lung-cell attachment and in vivo biofilm formation
[15,16]. Pilus is a long organelle that, like PsrP, extends beyond
the polysaccharide capsule and acts as an adhesin [17]. Finally,
PcpA is a choline-binding protein with a role in pneumococcal
adhesion and biofilm formation [18,19]. Determining the preva-
lence and distribution of these proteins in strains that cause IPD
and their correlation with disease and antibiotic resistance could
be of great value for future vaccine formulations.
Methods
Clinical Isolates
All pediatric invasive pneumococcal isolates characterized by
the Molecular Microbiology Department at University Hospital
Sant Joan de Deu in Barcelona, Spain from January 2004 to
December 2010 were included in this study. The department
performs molecular surveillance of pneumococci in Catalonia,
Spain. Clinical isolates were obtained from patients admitted to
Sant Joan de De´u Hospital and, since 2009, from patients attended
in 30 health centers throughout Catalonia region. In addition, we
also included eighty-nine pneumococcal strains isolated from
nasopharynx of healthy children during 2004–2008.
Serotyping and Antimicrobial Susceptibility
All isolates were serotyped by Quellung reaction at the National
Pneumococcus Reference Centre (Majadahonda, Madrid). Pneu-
mococcal isolates collected since 2009 were also serotyped by
Real-Time PCR (RT-PCR) using published protocols [20].
Serotypes were classified according to coverage of the existing
7,10, and 13-valent conjugate vaccines and their attack rate
according to the studies of Brueggemann et al. [21] and Sleeman
et al. [22]. Serotypes with high attack rate (those that are less apt to
be detected in carriage than in disease) included: 1, 4, 5, 7F, 9V,
14, 18C and 19A. Serotypes with low attack rate (that are less apt
to be detected in disease than in carriage) included: 3, 6A, 6B, 8,
9N, 10A, 11A, 12F, 13, 15A, 15BC, 16F, 17F, 19F, 20, 21, 22F,
23A, 23B, 23F, 24F, 27, 31, 33F, 35B, 35F, 37 and 38. Agar
dilution technique was used to determine the minimal inhibitory
concentrations (MICs) of penicillin and other antibiotics. Antibi-
otic susceptibility was defined according to the 2008 meningeal
breakpoints established by the Clinical Laboratory Standards
Institute [23]. Isolates with intermediate or high level resistance
were defined as non-susceptible.
Extraction of DNA
Genomic DNA was extracted from bacteria using Chelex-100
resin (BioRad Laboratories, Hercules, California, USA). Briefly,
pneumococci scraped from blood agar plates were suspended in
100 ml of PBS-buffer; 50 ml were transferred to a new micro-
centrifuge tube and vigorously vortexed with 150 ml of 20% w/v
Chelex-100 in PBS. The bacteria/resin suspensions were incubat-
ed for 20 minutes at 56uC followed by a 10-minute incubation at
100uC. After cooling and centrifugation, the supernatant was used
as a DNA template in PCR reactions.
Multilocus Sequence Typing (MLST)
Genetic characterization of pneumococci was performed using
MLST. In brief, internal fragments of the aroE, gdh, gki, recP, spi, xpt
and ddl genes were amplified by PCR using the primer pairs
described by Enright and Spratt [24]. PCR products were
sequenced using an ABI 3130xl GeneticAnalyzer (Applied
Biosystems). The sequences at each of the seven loci were then
compared with all of the known alleles at that locus. Sequences
that are identical to a known allele were assigned the same allele
number whereas those that differ from any known allele were
assigned new allele numbers. The assignment of alleles at each
locus was carried out using the software at the pneumococcal web
page: www.mlst.net. The alleles at each of the seven loci define the
allelic profile of each isolate and their sequence type (ST). Allelic
profiles are shown as the combination of 7 alleles in the order aroE,
gdh, gki, recP, spi, xpt and ddl. A clone is defined as a group of isolates
with identical allelic profile or ST.
Real-Time PCR Assay
We analyzed the nucleotide sequence of psrP, pilus-1 subunit rrgC,
and pcpA for primers in all publically available S. pneumoniae genomes
available through the United States National Center for Bio-
technology Information web site (http://www.ncbi.nlm.nih.gov/).
The primers and probe selected for psrP detection were: forward
primer: 59-CTTTACATTTACCCCTTACGCTGCTA; reverse
primer 39 CTGAGAGTGACTTAGACTGTGAAAGTG and
probe: FAM-CTGGTCGTGCTAGATTC (Quencher MGB).
These primers identified a conserved region within Basic Region
domain of PsrP. For pilus-1 detection the primers and probe were:
forward primer: 59-TTGTGACAAATCTTCCTCTTGGGA; re-
verse primer: 39-GTCACCAGCTGATGATCTACCA and probe:
FAM-CAGTGGCTCCACCTCC (Quencher MGB). These prim-
ers identified a conserved region within the structural subunit
protein RrgC encoded in the rlrA islet of pilus type 1. For pcpA
detection the primers and probe were: forward primer: 59-
GAAAAAGTAGATAATATAAAACAAGAAACTGATGTAGC-
TAAA; reverse primer: 39-ACCTTTGTCTTTAACCCAAC-
CAACT and probe: FAM-CTCCCTGATTAGAATTC (Quench-
er MGB). These primers identified a conserved region of N-terminal
fragment of PcpA. Finally, as a positive control and to test PCR
inhibitors and DNA quality, detection of ply gene by Real-Time
PCR was performed as previously described in all strains [25]. Ply
encodes the pneumolysin, a toxin found within all S.pneumoniae.
The reaction volume for each gene detected was a total of 25ml
and contained 5ml of DNA extract from samples or controls and
12.5ml 2X TaqMan Universal Master Mix (Applied Biosystems),
which includes dUTP and uracil-N-glycosylase; each primer was
used at a final concentration of 900 nM. The TaqMan probes
were used at a final concentration of 250 nM. DNA Amplification
was done performing universal amplification conditions: incuba-
tion for 2 min at 50uC (uracil-N-glycosylase digestion) and 10 min
denaturation at 95uC, 45 cycles of two-step amplification (15 s at
95uC, 60 s at 60uC). Amplification data were analyzed by SDS
software (Applied Biosystems). The reporter dye was measured
relative to the internal reference dye (ROX) signal to normalize for
non-PCR related fluorescence fluctuations occurring from well to
well. The cycle threshold (CT) value was defined as the cycle at
PcpA, PsrP and Pilus-1 of Streptococcus pneumoniae
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which the reporting dye fluorescence first exceeds the background
level.
Statistical Analysis
Statistical analysis was performed with the PASW software
package (version 17.0). Continuous variables were compared using
the t test (for approximately normally distributed data) or the
Mann-Whitney U test (for skewed data) and described as mean
values and standard deviations or median and interquartile range
P25–P75 (IQR) according to the presence of normal distribution.
Chi-square test or Fisher’s exact test (two-tailed) was used to
compare categorical variables. Comparison between groups was
performed by Kruskal-Wallis test. Statistical significance was set at
a P value of ,0.05.
Results
Strain Properties
Of the total 461 pediatric invasive pneumococcal isolates in our
library, 3 of them could not be recovered from stocks and were
thereby excluded from the study. As such, we examined a total of
458 invasive pneumococcal isolates and 89 nasopharyngeal
pneumococcal isolates among children (total = 547 strains).
The clinical syndromes were: pneumonia 257 (111 of them with
empyema), bacteremia 114, meningitis 68, arthritis 13, appendi-
citis 4, pericarditis 1 and peritonitis 1.
The most frequent serotypes detected among invasive isolates
were serotype 1 (n = 134), 19A (n = 84), 7F (n = 35), 5 (n = 34) and
14 (n = 19). Among carriers the most frequent serotypes were 19A
(n = 9), 6A (n = 9), 19F (n = 7), 15B (n = 6) and 23B (n = 6).
Figure 1. Prevalence of pcpA, psrP and pilus-1. (A) Prevalence for pcpA, psrP and pilus-1 alone and for their combinations (isolates with al least
one of the three combinations) in 458 pneumococcal isolates of patients with invasive pneumococcal disease (IPD) and in 89 pneumococcal isolates
of healthy nasopharyngeal carriers. (B) Prevalence of strains that carry all three proteins, and two of possible protein combinations including pcpA and
psrP, psrP and pilus-1, pcpA and pilus-1 among pneumococcal isolates of patients with IPD and healthy nasopharyngeal carriers.
doi:10.1371/journal.pone.0041587.g001
PcpA, PsrP and Pilus-1 of Streptococcus pneumoniae
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Among IPD isolates, the prevalence of serotypes included in the
commercialized conjugate vaccines PCV7, PCV10 and PCV13
were 14.2% (65 isolates), 58.3% (267 isolates) and 83.6% (383
isolates) respectively. The prevalence of serotypes included in the
three vaccines among isolates from the nasopharynx of healthy
carriers was 23.6% (21 isolates), 27% (24 isolates) and 50.6% (45
isolates).
With respect to clonal properties the most frequent clonotypes
among invasive isolates were ST306 (n = 107), ST191 (n = 31),
ST1223 (n = 25), ST304 (n = 22), ST276 (n = 17). A high variety of
clonotypes were detected in carriers (56 different clonotypes in 89
strains); the most frequent being ST2372 (n = 5), ST97 (n = 4),
ST42 (n = 3), ST63 (n = 3), ST180 (n = 3), ST838 (n = 3) and
ST2690 (n = 3). Finally, antibiotic susceptibility study was avail-
able in 543 of the 547 strains with 134 (24.5%) having diminished
penicillin susceptibility (MIC $0.12). The percentage of isolates
with diminished penicillin susceptibility was 23.4% (107 of 454)
among invasive isolates and 30.3% (27 of 89) among carriers.
Figure 2. Prevalence of pcpA, psrP and pilus-1 according to clinical syndrome among pneumococcal invasive isolates.
doi:10.1371/journal.pone.0041587.g002
Table 1. Prevalence of pcpA, psrP and pilus-1 according to antimicrobial susceptibility.
Antimicrobial agent pcpA psrP pilus-1
MIC Isolates % %Positive P %Positive P %Positive P
Penicillin
#0.06 409 75.3 90.2 ,.000 62.6 ,.000 8.8 ,.001
$0.12 134 24.7 100 17.9 34.3
Cefotaxime
#0.5 482 88.8 91.7 0.01 56.4 ,.000 9.3 ,.001
$1 61 11.2 100 13.1 60.7
Erythromicine
#0.25 415 76.4 90.6 0.001 58.3 ,.000 10.8 ,.001
$0.5 128 23.6 99.2 29.7 28.9
Tetracycline*
#2 409 75.9 91.4 0.07 58.9 ,.000 11.2 0.001
$4 130 24.1 96.2 28.5 27.7
Chloramphenicol**
#4 515 95.2 92.8 0.4 50.7 0.02 15.7 0.09
$8 26 4.8 88.5 73.1 3.8
The study was non-available in four* and six** isolates.
doi:10.1371/journal.pone.0041587.t001
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Overall Prevalence of PcpA, PsrP and Pilus-1
The individual prevalence of pcpA, psrP, and Pilus-1 in the 547
strains of our collection were 92.7%, 51.2% and 15% without
significant differences occurring between invasive and carrier
isolates: for pcpA 92.8% vs. 92.1%; P = 0.8, for psrP 51.7% vs.
48.3%; P = 0.5 and for pilus-1 14.4% vs. 18%; P = 0.3, respec-
tively. Given the high prevalence of pcpA the potential coverage
with at least one protein of a multivalent vaccine including these
three candidates would be high: 96.5% among invasive isolates
(442 of 458 isolates) and 94.4% among carriers (84 of 89 isolates).
Figure 1A shows the prevalence for each protein alone and for at
least 1 of the proteins in the specific combinations (PcpA/PsrP/
Pilus-1, PcpA/PsrP, PcpA/Pilus-1 and PsrP/Pilus-1). Notably, in
Figure 1B, we show that 96% of the invasive isolates carried at
least two of the three proteins, whereas 92% of the carrier isolates
did the same. Likewise, 6% of isolates carried all 3 proteins, (4%
and 8% of the invasive and carrier isolates, respectively). Thus, the
majority of individuals immunized with a vaccine composed of
these three antigens would have antibodies for at least 2 of these 3
proteins.
Prevalence Based on Clinical Symptom and Antibiotic
Resistance
The prevalence of pcpA among all strains was too high to have
any correlation with any clinical condition. In contrast, the
prevalence of psrP was significantly higher in patients with non
complicated pneumonia (58.2; %P,.001) or empyema (59.5%;
P,.001) than in children with bacteremia (40.4%). Inversely, the
prevalence of pilus-1 was greater in patients with bacteremia than
in patients with non-complicated (22.8% vs. 9.6%; P = 0.005) and
complicated pneumonia (11.7%; P = 0.04) (Figure 2). We also
observed significant differences in the prevalence of psrP and pilus-
1 according to susceptibility for different antimicrobials (Table 1).
Overall psrP was significantly more frequently detected in
penicillin, cefotaxime, erythromycin and tetracycline susceptible
isolates while pilus-1 and, to a modest level pcpA, were more
frequently detected in isolates non susceptible to these antimicro-
bials. In contrast, psrP was significantly more frequently detected in
chloramphenicol non-susceptible isolates.
Prevalence of pcpA, psrP and Pilus-1 According to
Serotype and Clonotype
Prevalence of these proteins was strongly associated with specific
serotype and clonotypes. Table 2 shows significant differences in
the prevalence of pcpA, psrP and pilus-1 according to serotype. pcpA
is highly prevalent in almost all serotypes, the exception being
serotype 3. pcpA was only detected in 7 of 21 isolates of serotype 3
(33.3%) vs. 500 of 526 non serotype 3 isolates (95.1%; P,.001).
Interestingly, for certain serotypes the prevalence of psrP was high
but occurred with an absence of pilus-1 or vice versa. For example,
the prevalence of psrP among 136 strains tested of serotype 1 was
80.1% (109 isolates) but pilus-1 was not detected in any strain of
Table 2. Prevalence of pcpA,psrP and Pilus-1 according to
serotype of isolates.
Serotype Isolates pcpA Pos % psrP Pos % pilus Pos %
Overall 547 507 92.7 280 51.2 82 15.0
1 136 132 97.1 109 80.1 0 0.0
19A 93 90 96.8 44 47.3 26 28.0
7F 36 36 100.0 4 11.1 0 0.0
5 34 28 82.4 30 88.2 0 0.0
6A 22 21 95.5 11 50.0 4 18.2
3 21 7 33.3 2 9.5 0 0.0
19F 20 16 80.0 13 65.0 6 30.0
14 19 19 100.0 1 5.3 16 84.2
6B 14 14 100.0 5 35.7 8 57.1
15B 13 13 100.0 10 76.9 2 15.4
9V 12 12 100.0 3 25.0 9 75.0
23B 12 12 100.0 1 8.3 0 0.0
24F 10 10 100.0 1 10.0 0 0.0
23F 10 10 100.0 1 10.0 0 0.0
10A 9 9 100.0 2 22.2 1 11.1
23A 6 6 100.0 4 66.7 0 0.0
18C 6 6 100.0 5 83.3 0 0.0
15C 6 6 100.0 5 83.3 1 16.7
38 6 3 50.0 2 33.3 2 33.3
21 5 5 100.0 3 60.0 0 0.0
4 5 3 60.0 4 80.0 4 80.0
15A 4 4 100.0 1 25.0 0 0.0
24 4 4 100.0 2 50.0 0 0.0
35B 3 3 100.0 1 33.3 1 33.3
22F 3 3 100.0 3 100.0 0 0.0
16F 3 3 100.0 3 100.0 0 0.0
12F 3 3 100.0 0 0.0 0 0.0
9N 2 2 100.0 1 50.0 0 0.0
37 2 2 100.0 0 0.0 0 0.0
34 2 1 50.0 0 0.0 1 50.0
31 2 2 100.0 0 0.0 0 0.0
29 2 2 100.0 1 50.0 0 0.0
28 2 1 50.0 0 0.0 0 0.0
27 2 1 50.0 0 0.0 0 0.0
22 2 2 100.0 1 50.0 0 0.0
16 2 2 100.0 2 100.0 0 0.0
6C 1 1 100.0 0 0.0 0 0.0
35F 1 1 100.0 1 100.0 0 0.0
33F 1 1 100.0 0 0.0 0 0.0
24B 1 1 100.0 0 0.0 0 0.0
17F 1 1 100.0 1 100.0 0 0.0
11A 1 1 100.0 0 0.0 0 0.0
47 1 1 100.0 0 0.0 1 100.0
39 1 1 100.0 1 100.0 0 0.0
17 1 1 100.0 0 0.0 0 0.0
13 1 1 100.0 1 100.0 0 0.0
11 1 1 100.0 1 100.0 0 0.0
Table 2. Cont.
Serotype Isolates pcpA Pos % psrP Pos % pilus Pos %
10 1 1 100.0 0 0.0 0 0.0
8 1 1 100.0 0 0.0 0 0.0
2 1 1 100.0 0 0.0 0 0.0
Pos: positive detection.
doi:10.1371/journal.pone.0041587.t002
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serotype 1. This observation was also detected for serotype 5
where psrP was detected in 88.2% of the 34 strains but Pilus-1 was
absent. In contrast, for serotypes 14 or 6B the prevalence of psrP
was significantly lower than the prevalence of pilus-1 (5.3% vs.
84.2% among serotype 14 isolates (n = 19) and 35.7% vs. 57.1%
among serotype 6B isolates (n = 14). Other serotypes without pilus-
1 included serotype 7F (none of 36 strains) and serotype 3 (none of
21 strains). psrP was also very low in these serotypes (11.1% for
serotype 7F and 9.5% for serotype 3). In fact, of all 547 strains
tested, only 4.2%, tested positive for both psrP and pilus-1.
Using the designation of serotypes having high or low attack
rate [21,22] psrP was significantly more frequent in serotypes
categorized as having high attack rate (those less apt to be detected
in carriage than in disease) than in serotypes categorized as low
attack rate (those less apt to be detected in disease than in carriage)
(58.7% vs. 39.1%; P,.001). pcpA was also more frequently
detected in serotypes with high attack rate (95.6% vs. 87.5%;
P = 0.01). Pilus-1 distribution was similar in high and low attack
rate serotypes (16.1% vs. 13.6%; P = 0.4). Considering only
penicillin susceptible isolates, the prevalence of psrP between high
and low attack rate serotypes was different (72.3% vs. 44.9%;
P,.001). The distribution of pcpA among these susceptible isolates
was also higher in high attack rate serotypes vs. low attack rate
serotypes (94.3% vs. 81.9%; P = 0.01). Among penicillin suscep-
tible isolates, the prevalence of Pilus-1 was higher in those
expressing serotypes that are less apt to be detected in disease than
in carriage (13.4% vs. 6.4%; P = 0.02). Figure 3 shows the
prevalence of PcpA, PsrP and Pilus-1 according to serotypes within
the commercialized conjugate vaccines. Pilus-1 was more frequent
detected among PCV7 serotypes vs. non PCV7 serotype 50% vs.
8.5%; P,001). In contrast, psrP was more frequent detected
among non PCV7 isolates vs PCV7 isolates (53.8% vs. 37.2%;
P = 0.005).
Finally, we observed stark and significant differences in
prevalence of these proteins according to clonotype among isolates
expressing the same serotype (Table 3). psrP was detected in almost
all ST306 (106 of 109 isolates; 97.2%) while practically in none of
the isolates with ST304 (1 of 22 isolates; 4.5%). Pilus-1 was totally
absent in these clonotypes. The same phenomenon was observed
for the penicillin susceptible clone ST1201: all isolates with this
clone (n = 19) have psrP, while none have Pilus-1. The opposite
was observed for multiresistant clone ST320, which all (n = 16)
have pilus-1 yet lack psrP. Even in pcpA, which has a high
prevalence within the entire collection, significant differences
according to clonotype were detected in strains expressing the
same serotype. For example, among isolates expressing serotype 3,
pcpA was detected in 100% of strains with ST260, ST1220,
ST1377 or ST2590 (6 isolates) while only in 6.6% of ST180 (1 of
15 isolates).
Discussion
Among IPD isolates, the prevalence of disease caused by
serotypes included in the commercialized conjugate vaccines
increased from 14.2% in PCV7 to 83.6% in PCV13. In contrast,
the overall prevalence of serotypes included in PCV13 in
nasopharynx was only 50.6%. Thus, even though the newly
introduced PCV13 vaccine had robust coverage against disease, its
intermediate coverage of the current colonizing serotypes leaves
open the possibility of serotype replacement by current invasive
clones or continuing serotype shift. In the same way that an
indirect effect of PCV7 preventing disease in adults and non-
vaccinated children had been observed [5,6], it is expected indirect
protection offered by herd immunity using multivalent pneumo-
coccal protein vaccines [26,27].
PcpA was highly prevalent in our collection, suggesting that it is a
conserved pneumococcal component. While previous studies,
including our own, have examined the prevalence of psrP or
pilus-1 alone among clinical isolates [28–31], to our knowledge no
information exists on the prevalence of pcpA. As indicated PcpA is
an adhesin, and immunization with recombinant protein has been
demonstrated to reduce the number of bacteria in the lungs of
mice challenged with S. pneumoniae and to increase survival time in
a mouse sepsis model following intraperitoneal challenge [19].
Most recently, PcpA has been shown to be required for in vitro
biofilm formation [32], upregulated in response to Zn(2+) [33],
and capable of eliciting antibodies during human nasopharyngeal
colonization and acute otitis media [34], but not during
bacteremia in infants [35]. Our finding that pcpA was present in
500 of the 526 serotypes, excluding serotype 3 isolates, underlines
Figure 3. Prevalence of pcpA, psrP and pilus-1 according to serotypes within the commercialized conjugate vaccines.
doi:10.1371/journal.pone.0041587.g003
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Table 3. Prevalence of pcpA. psrP and pilus-1 according to clonotypes (ST) detected in the study.
pcpA psrP pilus-1
ST Isolates Serotype Positive % Positive Positive % Positive Positive % Positive
306 109 1 (n = 109) 107 98.2 106 97.2 0 0.0
191 32 7F (n = 32) 32 100.0 3 9.4 0 0.0
1223 25 5 (n = 25) 23 92.0 21 84.0 0 0.0
304 22 1 (n = 22) 22 100.0 1 4.5 0 0.0
1201 19 19A (n = 19) 18 94.7 19 100.0 0 0.0
276 18 19A (n = 18) 18 100.0 3 16.7 0 0.0
320 16 19A (n = 16) 16 100.0 0 0.0 16 100.0
180 15 3 (n = 15) 1 6.7 1 6.7 0 0.0
156 13 14 (n = 13) 13 100.0 0 0.0 13 100.0
2013 13 19A (n = 13) 13 100.0 2 15.4 0 0.0
2372 12 23B (n = 10) 10 83.4 1 8.3 0 0.0
19A (n = 1) 1 8.3 1 8.3 1 8.3
23F (n = 1) 1 8.3 0 0 0 0
97 11 10A (n = 11) 11 100.0 2 18.2 1 9.1
289 8 5 (n = 8) 4 50.0 8 100.0 0 0.0
63 7 15A (n = 4) 4 57.1 1 14.3 0 0.0
15B (n = 1) 1 14.3 1 14.3 0 0.0
15C (n = 1) 1 14.3 0 0.0 0 0.0
38 (n = 1) 1 14.3 1 14.3 0 0.0
4677 6 24F (n = 6) 6 100.0 0 0.0 0 0.0
2100 6 19F (n = 6) 6 100.0 1 16.7 0 0.0
1167 6 19F (n = 5) 1 16.7 5 83.3 4 66.6
19A (n = 1) 0 0.0 1 16.7 1 16.7
838 6 9V (n = 6) 6 100.0 0 0.0 6 100.0
230 6 24F (n = 3) 3 50.0 0 0.0 0 0.0
24 (n = 2) 2 33.3 0 0.0 0 0.0
24B (n = 1) 1 16.7 0 0.0 0 0.0
202 6 19A (n = 6) 5 83.3 2 33.3 5 83.3
113 6 18C (n = 6) 6 100.0 5 83.3 0 0.0
199 5 19A (n = 4) 4 80.0 4 80.0 0 0.0
15B (n = 1) 1 20.0 1 20.0 0 0.0
42 5 23A (n = 5) 5 100.0 4 80.0 0 0.0
1262 4 15B (n = 2) 2 50.0 2 50.0 0 0.0
15C (n = 2) 2 50.0 2 50.0 0 0.0
433 4 22 (n = 1) 1 25.0 0 0.0 0 0.0
22F (n = 1) 1 25.0 1 25.0 0 0.0
19A (n = 1) 1 25.0 0 0.0 0 0.0
28 (n = 1) 1 25.0 0 0.0 0 0.0
416 4 19A (n = 4) 4 100.0 4 100.0 1 25.0
386 4 6B (n = 4) 4 100.0 1 25.0 2 50.0
90 4 6A (n = 2) 1 25.0 0 0.0 2 50.0
6B (n = 2) 2 50.0 0 0.0 2 50.0
81 4 19A (n = 2) 2 50.0 2 50.0 0 0.0
19F (n = 1) 1 25.0 1 25.0 0 0.0
23F (n = 1) 1 25.0 1 25.0 0 0.0
30 4 16 (n = 2) 2 50.0 2 50.0 0 0.0
16F (n = 2) 2 50.0 2 50.0 0 0.0
2690 3 29 (n = 2) 2 66.7 1 33.3 0 0.0
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the importance of this protein for pneumococcal biology and
strongly supports its inclusion in any protein vaccine.
Surprisingly, pcpA was only present in 7 of the 21 serotype 3
isolates tested. The absence of adhesins in serotype 3 isolates is not
unprecedented; Choline binding protein A (CbpA; also known as
PspC), which binds to both polymeric immunoglobulin receptor
and laminin receptor, and has been implicated in biofilm
formation, has a low prevalence within serotype 3 isolates [36].
Serotype 3 isolates are distinct from most other pneumococcal
serotypes in that they are exceedingly encapsulated, and therefore
appear highly mucoid on blood agar plates. The absence of these
adhesins and a distinct clinical profile suggest that serotype 3
isolates might have a pathogenesis dissimilar to other pneumo-
coccal isolates, as numerous studies indicate that capsular
polysaccharide inhibits bacterial adhesion, and serotype 3 isolates
are frequently associated with necrotizing pneumonia. This
suggests that a distinct protein vaccine formulation would be
required for protection against serotype 3-mediated disease. This
notion is supported by studies in experimentally infected mice,
where a serotype 3 clinical isolate remained in the lungs but
replicated to high titers, whereas clinical isolates of serotype 2 and
4 replicated to lower titers but caused disseminated disease [37].
PsrP is both an intraspecies and interspecies adhesin, mediating
attachment to Keratin 10 on lung cells and promoting the
presence of bacterial aggregates in vivo and biofilm formation
in vitro [38]. Pilus also functions as an adhesin, having been
demonstrated to mediate attachment to laminin and may also
contribute to the invasiveness of strains [39].
Importantly, considerable evidence indicates that immunization
of mice with either the basic region domain of PsrP or with
individual components of Pilus-1 mediates protection [16,40].
Using Real-Time PCR, we detected psrP in 51.2% of all clinical
isolates, whereas we detected pilus-1 in 15% of all isolates. This
was consistent with a past study where the prevalence of psrP in
clinical isolates was found to be 52.4% and with studies of
numerous other investigators where the prevalence of pilus-1 in
clinical isolates was found to be between 10–30% [30,31,41,42].
Our study expands on these past studies by providing the
prevalence of these candidate vaccine antigens simultaneously.
There by assessing the potential coverage of a multivalent vaccine
composed of pcpA, psrP and pilus-1. In all, 96% of the strains
examined carried at least 1 of these proteins, 96% carried 2, and
6% carried all 3. Our analysis determined that psrP and pilus-1
have a negative correlation in multiple serotypes raising the
possibility that psrP and pilus-1 may have redundant roles, or that
their production might be metabolically expensive and that an
individual strain cannot support production of both of these
extremely large proteins. Briefly, PsrP is a glycosylated surface
protein that separates at a molecular weight .2000 kDa, whereas
Pilus-1 is primarily composed of multiple repeats of the subunit
RrgB. Both extend beyond the bacterial capsule to mediate
adhesion. Interestingly, our study shows that psrP was found
significantly among serotypes that are less apt to be detected in
carriage than in disease, while Pilus-1 was not associated with
these virulent serotypes. These data could suggest that PsrP is in
part responsible for the increased virulence of high attack rate
serotypes. Along this line, it is known that variation in virulence
exists among isolates of the same serotype, due to the contribution
of serotype-independent factors associated with clonal type [43].
The variability of the prevalence of pcpA, psrP and pilus-1
according to clonal type in strains expressing the same serotype
confirms that the presence of these factors appears to be a clonal
property. This fact has been reported for Pilus-1 by other authors
[41].
Table 3. Cont.
pcpA psrP pilus-1
ST Isolates Serotype Positive % Positive Positive % Positive Positive % Positive
21 (n = 1) 1 33.3 0 0.0 0 0.0
1684 3 31 (n = 2) 2 66.7 0 0.0 0 0.0
1 (n = 1) 1 33.3 0 0.0 0 0.0
1143 3 6A (n = 3) 3 100.0 3 100.0 1 33.3
310 3 38 (n = 2) 0 0.0 0 0.0 2 66.7
34 (n = 1) 0 0.0 0 0.0 1 33.3
280 3 9V (n = 2) 2 66.7 2 66.7 0 0.0
9N (n = 1) 1 33.3 1 33.3 0 0.0
224 3 6A (n = 3) 3 100.0 0 0.0 0 0.0
193 3 21 (n = 2) 2 66.7 2 66.7 0 0.0
15B (n = 1) 1 33.3 1 33.3 0 0.0
101 3 15C (n = 2) 2 66.7 2 66.7 0 0.0
15B (n = 1) 1 33.3 0 0.0 0 0.0
72 3 24 (n = 2) 2 66.7 2 66.7 0 0.0
24F (n = 1) 1 33.3 1 33.3 0 0.0
Other ST detected with 2 isolates each: ST62, ST109, ST162, ST177, ST338, ST393, ST439, ST447, ST558, ST989, ST1011, ST1220, ST1377, ST1624, ST1692, ST2611, ST2948,
ST4310, ST4828, ST5223, and ST5740.
1 isolate each: ST9, ST66, ST88, ST94, ST110, ST124, ST143, ST176, ST179, ST205, ST217, ST228, ST245, ST260, ST274, ST311, ST315, ST327, ST343, ST392, ST404, ST425,
ST446, ST450, ST460, ST494, ST557, ST614, ST876, ST994, ST1012, ST1064, ST1264, ST1475, ST1504, ST1577, ST1589, ST1611, ST1664, ST1844, ST1848, ST2319, ST2333,
ST2376, ST2377, ST2467, ST2557, ST2590, ST2592, ST2594, ST2595, ST2618, ST2946, ST2947, ST2949, ST3254, ST3259, ST3436, ST3437, ST3438, ST3490, ST3609, ST3787,
ST4306, ST4676, ST4796, ST4826, ST4832, ST4834, ST5224, ST5741, ST5825, ST5829, ST6006, ST6040, ST6394, ST6518 and ST6519.
doi:10.1371/journal.pone.0041587.t003
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Antibiotic resistance was associated with the presence of pilus-1
and showed a negative correlation with psrP. The association of
pilus-1 with antibiotic resistance has been reported previously, but
the reasons for this association are not clear. It could be that the
rrlA islet and specific resistance genes might be recombined
together. Moschioni et al. suggest that pilus aid in adhesion during
colonization of the nasopharynx and that pilus expressing strains
could be selected as a result of antibiotic treatment [44]. The
reason for negative association of psrP with resistant strains is
unknown. Interestingly, psrP had greater correlation with strains
isolated from individuals with pneumonia, both uncomplicated
and complicated, whereas Pilus-1 had a predilection for strains
associated with bacteremia. This observation is consistent with the
known roles of PsrP as a lung cell adhesin and Pilus-1 as a
mediator of invasive disease [17].
A limitation of the study is that the absence or presence of these
genes/proteins is based on PCR results of wellknown and
published genes [15,18,44] but potential primer divergence could
implied that a PCR negative result is not necessary equivalent of
the absence of the protein and viceversa.
In summary, our results indicate that pcpA is highly prevalent
and its addition to a multivalent pneumococcal protein vaccine
would result in considerable coverage. In contrast, psrP and pilus-1
have less robust individual coverage but, since psrP is present in
high attack rate strains and pilus-1 in antibiotic resistant strains,
could be added in an effort to reduce the likelihood of disease. The
inverse correlation of these proteins suggests that they could be
paired as part of a multi-valent vaccine to compensate for each
other. This notion is highlighted by the fact that 96% of all strains
carried pcpA and either psrP or pilus 1. Future studies are planned
to determine the protective efficacy of this trivalent vaccine against
invasive disease caused by multiple clinical isolates.
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